HIF1A and sarcoma: MS-275 treatment enhances YB-1 acetylation and lowers deacetylation, prevents the binding of factors such as HIF1a and G3BP1 to its mRNA, suppresses pro-metastatic activity via reducing YB-1 translation, and reduces sarcoma metastasis.